First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years’ experience
Authors:
- 24 September 2022
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (11) , 2405-2412
Abstract
Rabbit antithymocyte globulin (rATG) instead of horse ATG has been used for severe aplastic anemia (SAA) patients in China. This study aimed to investigate the hematologic responses and long-term overall survival (OS) outcomes in SAA patients who received rATG and cyclosporine as first-line immunosuppressive therapy. We analyzed data of 542 SAA patients treated with this therapy between 2005 and 2019. The median age was 20 (range, 2–80) years, and the median follow-up time was 45.5 (range, 0.1–191.4) months. The early mortality rate was 3.9%. The overall response rates (ORRs) were 40.2%, 56.1%, and 62.4% at 3, 6, and 12 months, respectively. The 6- and 12-month ORR of patients treated with 3 mg/kg/d of rATG in 2015–2019 seemed higher than that of patients treated with 3.5–3.75 mg/kg/day in 2005–2014 (60.2% vs. 54.9%, P = 0.30 and 69.9% vs. 60.1%, P = 0.049, respectively). The 10-year cumulative incidences of relapse and clonal evolution were 10.6 ± 2.9% and 7.5 ± 1.5%, respectively. The 10-year OS rate and event-free survival rate were 80.1 ± 2.1% and 75.6 ± 3.7%, respectively. Age, disease severity, treatment periods, and the interval from diagnosis to IST were independent predictors of OS. In conclusion, 3 mg/kg/day rATG is effective as first-line treatment for SAA.Keywords
Funding Information
- National Natural Science Foundation of China (81900127)
This publication has 31 references indexed in Scilit:
- Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemiaInternational Journal of Hematology, 2013
- Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working PartyBlood, 2012
- Rabbit-antithymocyte globulin combined with cyclosporin A as a first-line therapy: improved, effective, and safe for children with acquired severe aplastic anemiaJournal of Cancer Research and Clinical Oncology, 2012
- Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic AnemiaNew England Journal of Medicine, 2011
- Epidemiology of aplastic anemia: a prospective multicenter studyHaematologica, 2008
- The epidemiology of acquired aplastic anemiaHaematologica, 2008
- Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long‐term observation follow‐upBritish Journal of Haematology, 2007
- Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in JapanBlood, 2007
- The epidemiology of aplastic anemia in ThailandBlood, 2006
- Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT* SAA Working PartyBritish Journal of Haematology, 1988